drugset
drugset / Trial / NCT00417807

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

NCT00417807 ↗

Phase 1/2 Completed 9 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, non-comparative study conducted to investigate the activity and safety of imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R. Patients will be treated up to 12 months, or to disease progression. Tumor will be evaluated according to Recist criteria

Timeline

Start
2005-08
Primary completion
2009-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — —

Indications

desmoplastic small round cell tumor